NCT04195828

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Completed Phase 2 Last updated 1 April 2025

What this trial tests

Phase 2 trial testing Camrelizumab in Advanced Gastric Cancer in 106 participants. Completed in 24 March 2025.

Timeline

18 June 2020

Primary endpoint
22 July 2022

24 March 2025

Quick facts

Lead sponsor	Fujian Medical University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	106
Start date	18 June 2020
Primary completion	22 July 2022
Estimated completion	24 March 2025
Sites	1 location across China

Drugs / interventions tested

• Camrelizumab — full drug profile →
• Apatinib Mesylate
• nab-paclitaxel (nab-paclitaxel) — full drug profile →
• S1 — full drug profile →

Conditions studied

• Advanced Gastric Cancer — all drugs for Advanced Gastric Cancer →

Sponsor

Fujian Medical University

Who can join

Adults 18 to 75, any sex, with Advanced Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.
   Lin JX, Tang YH, Zheng HL, Ye K, et al · · 2024 · cited 52× · PMID 38167806 · DOI 10.1038/s41467-023-44309-5
2. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies.
   Luo D, Zhou J, Ruan S, Zhang B, et al · · 2025 · cited 27× · PMID 39915459 · DOI 10.1038/s41419-025-07385-7
3. Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing.
   Lavacchi D, Fancelli S, Buttitta E, Vannini G, et al · · 2023 · cited 11× · PMID 36902306 · DOI 10.3390/ijms24054877
4. Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy.
   Lin GT, Yan C, Li LJ, Qiu XW, et al · · 2025 · cited 4× · PMID 40053469 · DOI 10.1158/0008-5472.can-24-2697
5. Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report.
   Zhao J, Li X, Sun X, Xiao R, et al · · 2025 · cited 4× · PMID 40040691 · DOI 10.3389/fimmu.2025.1533700
6. Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma.
   Liu X, Ma B, Zhao L. · · 2024 · cited 4× · PMID 38686192 · DOI 10.3389/fonc.2024.1342162
7. Programmed death receptor-1/programmed death-ligand 1 inhibitors: Clinical progress and biomarker exploration in gastric cancer.
   Shi J, Song X, Gao Z, Dai D, et al · · 2024 · cited 3× · PMID 39640802 · DOI 10.1016/j.heliyon.2024.e38710
8. Neoadjuvant sintilimab and apatinib combined with perioperative FLOT chemotherapy for locally advanced gastric cancer: A prospective, single-arm, phase II study.
   Zhou H, Long B, Yu Z, Zhu J, et al · · 2024 · cited 2× · PMID 39317970 · DOI 10.1097/cm9.0000000000003303